BioSpace News Archive

- Labelling Discussions with the FDA are Underway for HTX-011; Prescription Drug User Fee Act (PDUFA) Goal Date is May 12, 2021 -

Community Hospital Corporation announced that it recently surpassed a major milestone.

Growing awareness for cancer treatment and better healthcare infrastructure are positively influencing MRI-guided radiation therapy systems market sales.

Update on Ii-Key-SARS-CoV-2 vaccine program Appointment of Dr. Craig Eagle to be Chairman of the Board of NuGenerex Immuno-Oncology Inc. pending board approval. Re-Launch of Excellagen® in the VA Hospital Network Launch of Remote Patient Monitoring (RPM) Business NuGenHealth Update on Partnership & Anticipated Acquisition of AltuCell

Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the first quarter ended March 31, 2021.

Inova Diagnostics, a world leader in autoimmune disease diagnostic systems and reagents for the clinical laboratory, is pleased to announce the Emergency Use Authorization of QUANTA Flash SARS-CoV-2 IgG by the US Food and Drug Administration (FDA) for use on BIO-FLASH® random access chemiluminescent analyzer.

Therapeutic Solutions International, Inc., (OTC Markets: TSOI), and its subsidiary Campbell Neurosciences announced today new data covered by its previously filed patents supporting the use of mesenchymal based stem cell therapy for schizophrenia.

Medicus IT (MIT), the leading healthcare-focused managed services provider (MSP) based in Alpharetta, Georgia, announced the acquisition of Health Information Technology Care (HITCare), California’s premier healthcare managed IT services provider based in Petaluma.

Strengthens investor syndicate with SV’s Impact Medicine Fund, MRL Ventures and Sanofi Ventures joining to accelerate development of disease-modifying drugs for dementia and other inflammatory conditions.

Flow Eighteen38 and FairJourney Biologics S.A. (FJB), leaders in the discovery and optimization of antibodies, have today announced an agreement with the Hubrecht Institute to harness the potential of FJB’s proprietary llama naïve libraries to develop antibodies to be used as research tools for the group of Hans Clevers.